Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference

Friday, June 9, 2017 8:30 am EDT

Dateline:

CHARLESTON, S.C.

Public Company Information:

NASDAQ:
AEZS
TSX:
AEZS
CA0079754028

CHARLESTON, S.C.--(BUSINESS WIRE)--Aeterna Zentaris Inc. (TSX: AEZS) (NASDAQ: AEZS) (the “Company”) today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the 2017 Marcum MicroCap Conference on Friday, June 16, 2017 at 9:30 a.m. (Eastern) in New York City. A copy of the presentation will be available on the Company’s website at www.aezsinc.com.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. We are engaged in drug development activities and in the promotion of products for others. We recently completed Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition of licenses to products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.

Contact:

Aeterna Zentaris
Philip A. Theodore, 843-900-3223
Senior Vice President
ir@aezsinc.com